Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment
Publication
, Journal Article
Friedman, HS
Published in: Oncology Report
September 1, 2006
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2006
Issue
FALL
Start / End Page
11
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2006). Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment. Oncology Report, (FALL), 11.
Friedman, H. S. “Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment.” Oncology Report, no. FALL (September 1, 2006): 11.
Friedman HS. Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment. Oncology Report. 2006 Sep 1;(FALL):11.
Friedman, H. S. “Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment.” Oncology Report, no. FALL, Sept. 2006, p. 11.
Friedman HS. Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment. Oncology Report. 2006 Sep 1;(FALL):11.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2006
Issue
FALL
Start / End Page
11
Related Subject Headings
- Oncology & Carcinogenesis